EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

This publication has 23 references indexed in Scilit:

• In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity
  British Journal of Cancer, 1992
• The Role of NAD(P)H: Quinone Reductase (EC 1.6.99.2, DT-Diaphorase) in the Reductive Bioactivation of the Novel Indoloquinone Antitumor Agent E09
  Cancer Communications, 1991
• Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines
  JNCI Journal of the National Cancer Institute, 1991
• The clonogenic assay with human tumor xenografts: Evaluation, predictive value and application for drug screening
  Annals of Oncology, 1990
• New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
  JNCI Journal of the National Cancer Institute, 1990
• DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?
  British Journal of Cancer, 1989
• Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm
  JNCI Journal of the National Cancer Institute, 1989
• The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay
  International Journal of Radiation Oncology*Biology*Physics, 1989
• Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development
  European Journal of Cancer and Clinical Oncology, 1987
• Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents
  Tetrahedron, 1987